Media stories about Alder BioPharmaceuticals (NASDAQ:ALDR) have trended somewhat positive recently, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Alder BioPharmaceuticals earned a news impact score of 0.09 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.2552014987148 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the news headlines that may have impacted Accern Sentiment’s scoring:

Alder BioPharmaceuticals (ALDR) traded up 5.08% during midday trading on Friday, reaching $9.30. 1,416,650 shares of the company traded hands. The company’s 50-day moving average price is $11.56 and its 200 day moving average price is $18.22. Alder BioPharmaceuticals has a 12 month low of $8.80 and a 12 month high of $36.48. The firm’s market capitalization is $629.73 million.

Alder BioPharmaceuticals (NASDAQ:ALDR) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.48) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.67) by $0.19. The firm had revenue of $0.68 million during the quarter. The company’s quarterly revenue was up 518.2% compared to the same quarter last year. During the same quarter last year, the business posted ($0.79) EPS. On average, equities analysts anticipate that Alder BioPharmaceuticals will post ($5.82) earnings per share for the current year.

Several research firms have recently weighed in on ALDR. Leerink Swann reissued an “outperform” rating and issued a $32.00 price target on shares of Alder BioPharmaceuticals in a research note on Monday, June 12th. Needham & Company LLC set a $36.00 price target on shares of Alder BioPharmaceuticals and gave the stock a “buy” rating in a research note on Monday, July 17th. Zacks Investment Research cut shares of Alder BioPharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 8th. UBS AG started coverage on shares of Alder BioPharmaceuticals in a research report on Friday, May 5th. They set a “sell” rating and a $13.00 price objective for the company. Finally, ValuEngine cut shares of Alder BioPharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, June 29th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the stock. Alder BioPharmaceuticals currently has an average rating of “Buy” and an average price target of $32.92.

ILLEGAL ACTIVITY WARNING: “Alder BioPharmaceuticals (NASDAQ:ALDR) Getting Somewhat Favorable News Coverage, Report Shows” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/13/alder-biopharmaceuticals-nasdaqaldr-getting-somewhat-favorable-news-coverage-report-shows.html.

In other news, Director Stephen M. Dow bought 25,000 shares of Alder BioPharmaceuticals stock in a transaction on Tuesday, July 18th. The shares were bought at an average cost of $10.00 per share, for a total transaction of $250,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. 10.60% of the stock is currently owned by corporate insiders.

About Alder BioPharmaceuticals

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Insider Buying and Selling by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Stock Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related stocks with our FREE daily email newsletter.